Whence and whither the fixed-dose combination?

Diabetes and Vascular Disease Research

Volumn 2, Issue 2, 2005, Pages 51-53

  Bailey, Clifford J ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS ATORVASTATIN; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; GLIBENCLAMIDE PLUS METFORMIN; GLIMEPIRIDE PLUS ROSIGLITAZONE; GLIPIZIDE PLUS METFORMIN; LOVASTATIN PLUS NICOTINIC ACID; METFORMIN PLUS ROSIGLITAZONE; MEVINOLIN; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; UNCLASSIFIED DRUG;

COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; EDITORIAL; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LICENSING; NON INSULIN DEPENDENT DIABETES MELLITUS;

EID: 20444506883     PISSN: 14791641     EISSN: None     Source Type: Journal    
DOI: 10.3132/dvdr.2005.008     Document Type: Editorial

References (18)

1. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281:2005-12.
2. Campbell IW. Need for intensive, early glycaemic control in patients with type 2 diabetes. Br J Cardiol 2000;7:625-31.
3. Hermann LS, Schersten B, Bitzen PO et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care 1994;17:1100-09.
4. Garber AJ, Larsen J, Schneider SH et al. Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diabetes Obesity Metab 2002;4:201-08.
5. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Clinical practice guidelines for the prevention and management of diabetes in Canada. Targets for glycemic control. Can J Diabetes 2003;27(suppl 2):S37-S42. (http://www.diabetes.ca/cpg2003/ downloads/pharmacologic.pdf last accessed March 2005).
6. Donnan PT, MacDonald TM, Morris AD for the DARTS/MEMO collaboration. Adherence to prescribed oral hypoglycaemic medication in a population of patients with type 2 diabetes: a retrospective cohort study. Diabetic Med 2002;19:279-84.
7. Emslie-Smith A, Dowall J, Morris A. The problem of polypharmacy in type 2 diabetes. Br J Diabetes Vasc Dis 2003;3:54-6.
8. Melikian C, White TJ, Vanderplas A et al. Adherence to oral antidiabetic therapy in a managed care organisation: a comparison of monotherapy, combination, and fixed-dose combination therapy. Clin Therapeutics 2002;24:460-7.
9. Garber AJ, Donovan DS, Dandona P et al. Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. J Clin Endocrinol Metab 2003;88:3598-604.
10. Bailey CJ, Day C. Avandamet: combined metformin-rosiglitazone treatment against insulin resistance in type 2 diabetes. Int J Clin Pract 2004;58:867-76.
11. Bajaj M, DeFronzo RA. Combination therapy in type 2 diabetes. In International Textbook of Diabetes Mellitus, 3rd edn. DeFronzo RA, Ferrannini E, Keen H, Zimmet P eds. Wiley: Chichester 2004, 915-50.
12. McCluskey D, Touger MS, Melis R, Schleusener DS. Result of a randomized double-blind, placebo controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapy. Clin Therapeutics 2004;26:1783-90.
13. Rendell MS, Glazer NB, Ye Z. Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with type 2 diabetes: influence of prior antidiabetic drug regimen. J Diabetes Complications 2003;17:211-17.
14. Skolnik NS, Beck JD, Clark M. Combination antihypertensive drugs: recommendations for use. Am Family Physician 2000;61:3049-56.
15. Weir MR. When antihypertensive monotherapy fails: fixed-dose combination therapy. South Med J 2000;93:548-56.
16. Bailey CJ. New drugs for the treatment of diabetes mellitus. In International Textbook of Diabetes Mellitus, 3rd edn. DeFronzo RA, Ferrannini E, Keen H, Zimmet P eds. Wiley: Chichester 2004, 951-79.
17. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. Br Med J 2003;326:1419-23.
18. Gaede P, Vedel P, Larsen N et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348:383-93.